Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases, , Wiley, John Wiley & Sons,Pharmacology,Medical specialties, branches of medicine, Quantitative Pharmacology; Individualized Therapy Strategies; Therapeutic Proteins; Development of Therapeutic Proteins; Immune-Mediated Inflammatory Diseases; IMIDs; biopharmaceutical; biologic medications; ADME of therapeutic proteins; translational pharmacodynamic modeling; pharmacokinetic modeling; pharmacology; pharmacometrics; systems pharmacology; autoimmune disorders; guselkumab; ustekinumab; daclizumab; natalizumab; belimumab; vedolizumab; peginterferon beta-1a; FcRn; pathophysiology of autoimmune diseases; biomarkers in autoimmune diseases; biochemistry; biotechnology; bridging to pediatrics; Pharmaceutical development; biosimilar drugs; development of biopharmaceuticals; post-translational modifications; toxicology; immunology; biochemistry; molecular biology; crohn's disease; lupus; plaque psoriasis; ulcerative colitis; Crohn's Disease; inflammatory bowel disease; immunomodulating medications; infliximab; adalimumab; etanercept; psoriatic arthritis; recombinant therapeutic proteins; certolizumab; etanercept; guselkumab; ustekinumab; daclizumab; natalizumab; belimumab; vedolizumab; peginterferon beta-1a,, , United States, en-UShttps://www.wiley.comQuantitative Pharmacology; Individualized Therapy Strategies; Therapeutic Proteins; Development of Therapeutic Proteins; Immune-Mediated Inflammatory Diseases; IMIDs; biopharmaceutical; biologic medications; ADME of therapeutic proteins; translational pharmacodynamic modeling; pharmacokinetic modeling; pharmacology; pharmacometrics; systems pharmacology; autoimmune disorders; guselkumab; ustekinumab; daclizumab; natalizumab; belimumab; vedolizumab; peginterferon beta-1a; FcRn; pathophysiology of autoimmune diseases; biomarkers in autoimmune diseases; biochemistry; biotechnology; bridging to pediatrics; Pharmaceutical development; biosimilar drugs; development of biopharmaceuticals; post-translational modifications; toxicology; immunology; biochemistry; molecular biology; crohn's disease; lupus; plaque psoriasis; ulcerative colitis; Crohn's Disease; inflammatory bowel disease; immunomodulating medications; infliximab; adalimumab; etanercept; psoriatic arthritis; recombinant therapeutic proteins; certolizumab; etanercept; guselkumab; ustekinumab; daclizumab; natalizumab; belimumab; vedolizumab; peginterferon beta-1a, [BLURB],[CITY],,books, ebooks, biblet, Book2look